E. Ke

发表

Distribution and prognosis of uncommon metastases from non-small cell lung cancer

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, BMC Cancer.

EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?

Yi-long Wu, Yi-Long Wu, E-E -Ke, 2016, Trends in pharmacological sciences.

Intratumoral genetic and immune microenvironmental heterogeneity in T4N0M0 (diameter ≥ 7 cm) non‐small cell lung cancers

X. Yi, Xue-Ning Yang, W. Zhong, 2022, Thoracic cancer.

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2017, Lung cancer.

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma

Jin-Ji Yang, Yilong Wu, Chongrui Xu, 2016, Oncotarget.

Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence

Yi-long Wu, E. Ke, 2016, Therapeutic advances in respiratory disease.

Emerging paradigms in targeted treatments for Asian patients with NSCLC

Yi-long Wu, Qing Zhou, E. Ke, 2015, Expert opinion on pharmacotherapy.

EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third‐Generation EGFR Tyrosine Kinase Inhibitor Osimertinib

Yi-long Wu, Jin-Ji Yang, Z. Wang, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.

Yi-long Wu, Jin-Ji Yang, Jie Huang, 2021, Clinical lung cancer.

Distribution and prognosis of uncommon metastases from non-small cell lung cancer

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, BMC Cancer.

First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial

Yangqiu Li, Jin-Ji Yang, Chongrui Xu, 2023, Nature Network Boston.

Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy

Jin-Ji Yang, W. Zhong, K. Yin, 2023, Molecular oncology.

PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial.

Jin-Ji Yang, Chongrui Xu, Xuchao Zhang, 2023, Science bulletin.